Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …

ContextRecently published results suggest that effective vaccines against cervical cancer—
associated human papillomavirus (HPV) may become available within the next decade …

Background The availability of human papillomavirus (HPV) DNA testing and vaccination
against HPV types 16 and 18 (HPV-16, 18) motivates questions about the cost-effectiveness …

The object of our study is to project the impact of a prophylactic vaccine against persistent
human papillomavirus (HPV)‐16/18 infection on age‐specific incidence of invasive cervical …

Background Human papillomavirus (HPV)–related disease remains a significant source of
morbidity and mortality, and this underscores the need to increase HPV vaccination to …

Background: Current US cervical cancer screening guidelines do not differentiate
recommendations based on a woman's human papillomavirus (HPV) vaccination status …

Human papillomavirus (HPV) is one of the most common sexually transmitted diseases
(STDs) and is frequently presented clinically as anogenital warts in both males and females …

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor
for cervical cancer. Given the substantial disease and death associated with HPV and …

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical
cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated …

We present a transmission dynamic model that can assess the epidemiologic consequences
and cost-effectiveness of alternative strategies of administering a prophylactic quadrivalent …